Meeting Details - The fourth temporary shareholders' meeting of Henan Tailong Pharmaceutical Co., Ltd. was held on November 14, 2025, at the company's conference room in Zhengzhou [1] - All 9 current directors attended the meeting, along with the board secretary and other senior executives [2] - The meeting was conducted in compliance with the Company Law and the company's articles of association, using a combination of on-site and online voting [1][2] Resolutions Passed - The profit distribution plan for the first three quarters of 2025 was approved [1] - The proposal to apply for the registration and issuance of medium-term notes was also approved [1] Legal Verification - The meeting was witnessed by Henan Qianwen Law Firm, confirming that the procedures and resolutions were in accordance with relevant laws and regulations [4] Company Changes - The wholly-owned subsidiary, Tongjuntang Pharmaceutical Co., Ltd., completed changes in its legal representative, board members, and business scope, and obtained a new business license from the Zhejiang Provincial Market Supervision Administration [6][7] - The registered capital of Tongjuntang Pharmaceutical Co., Ltd. is RMB 250 million, and it was established on November 30, 2005 [7]